MedPath
HSA Approval

XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED PEN 75MG/0.5ML

SIN17030P

XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED PEN 75MG/0.5ML

XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED PEN 75MG/0.5ML

June 21, 2024

NOVARTIS (SINGAPORE) PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantNOVARTIS (SINGAPORE) PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

INJECTION, SOLUTION

SUBCUTANEOUS

Medical Information

R03DX05

Manufacturer Information

NOVARTIS (SINGAPORE) PTE LTD

Novartis Pharma Stein AG

Active Ingredients

Omalizumab

75.00 mg/0.5 mL

Omalizumab

Documents

Package Inserts

Xolair PI.pdf

Approved: June 21, 2024

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED PEN 75MG/0.5ML - HSA Approval | MedPath